Text Size

Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
AMAG Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01114217
First received: April 29, 2010
Last updated: February 11, 2013
Last verified: February 2013
History of Changes
  Purpose

To evaluate the safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia (IDA).


Condition Intervention Phase
Iron Deficiency Anemia
 Drug: Ferumoxytol
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

Resource links provided by NLM:

MedlinePlus related topics: Anemia Iron
Drug Information available for: Ferumoxytol
U.S. FDA Resources

Further study details as provided by AMAG Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Hemoglobin changes [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Patient reported outcomes [ Designated as safety issue: No ]

Estimated Enrollment: 600
Study Start Date: July 2010
Estimated Study Completion Date: April 2013
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ferumoxytol
Safety and efficacy of intravenous (IV) ferumoxytol for the treatment of iron deficiency anemia (IDA)
 Drug: Ferumoxytol
IV Ferumoxytol
Other Name: Feraheme

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria include:

  1. Subjects who completed participation in study AMAG-FER-IDA-301
  2. Female subjects of childbearing potential who are sexually active must be on an effective method of birth control and agree to remain on birth control until completion of participation in the study

Key Exclusion Criteria include:

  1. Experienced a serious adverse event (SAE) related to ferumoxytol in study AMAG-FER-IDA-301
  2. Female subjects who are pregnant, intend to become pregnant, are breastfeeding, or have a positive serum/urine pregnancy test
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01114217

Locations
United States, Massachusetts
AMAG Pharmaceutcials, Inc.
Lexington, Massachusetts, United States, 02421
Sponsors and Collaborators
AMAG Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: AMAG Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01114217     History of Changes
Other Study ID Numbers: AMAG-FER-IDA-303
Study First Received: April 29, 2010
Last Updated: February 11, 2013
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
India: Central Drugs Standard Control Organization

Keywords provided by AMAG Pharmaceuticals, Inc.:
Iron deficiency anemia
Feraheme
ferumoxytol
AUB
 cancer
GI disorders
postpartum anemia
The treatment of iron deficiency anemia (IDA)

Additional relevant MeSH terms:
Anemia
Deficiency Diseases
Anemia, Iron-Deficiency
Hematologic Diseases
Malnutrition
Nutrition Disorders
Anemia, Hypochromic
Iron Metabolism Disorders
Metabolic Diseases
Ferumoxytol
 Iron
Hematinics
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 19, 2013